Navigation Links
Phidea Srl and Marvin Research Srl Announce Completion of Merger
Date:1/22/2009

MILAN, Italy, January 22 /PRNewswire/ -- Phidea S.r.l. a full service and leading clinical research organization (CRO), today announced that it has completed the merger with Marvin Research S.r.l., a CRO focused on Phase I to Phase IV clinical trials.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080122/335477 )

The new company will be named Phidea Marvin S.r.l. and have legal and operating offices in Milan, Italy. The combined company will also continue to operate its offices in Madrid, Spain providing drug development services to companies in need of a single source for clinical research including design and management of pan-European clinical trials (Phase I - III), and post marketing studies (Phase IV). Services offered by the new company will include all aspects of the clinical trial process including: protocol design, regulatory affairs, site selection, clinical monitoring, data management, statistical analysis and medical writing. Observational and epidemiological studies will also continue to be performed.

Phidea Marvin specializes in cardiovascular, CNS, gastroenterology oncology, rheumatology and anti-infective studies and services a broad range of multinational pharmaceutical firms.

Vincenzo Cocuzza, M.D., Phidea-Marvin's Chief Executive Officer stated, "We believe that this combination broadens our client base even further then it was, and provides the necessary platform for growth. We have a compelling strategy to expand operations into global markets and especially the United States and will continue to look for strategic opportunities that allow us to realize our goals. The merger with Marvin moves us closer to our objectives by:

    - Adding a partner with a strong market position and reputation in
      specific therapeutic areas

    - Adding additional multinational customers

    - Reducing costs

    - Increasing the overall size of the organization to allow even larger
      studies to be performed.

We also believe that the Marvin and Phidea teams have built an impressive portfolio of accomplishments and will work together to become a leader in the CRO sector."

About Phidea S.r.l.

Phidea S.r.l. specializes in international clinical research. The firm was founded in 1982 in Milan, Italy. In 1991 it expanded its operations and organized its Spanish subsidiary, Phidea Spain, in Madrid, Spain. The firm and partners provide a complete range of services to pharmaceutical companies including product formulation, stability, clinical trial material manufacturing, and all phases of clinical research.

Staffed with renown scientist and medical doctors, Phidea services major pharmaceutical companies seeking premium research in the European Union.

About Marvin Research S.r.l.

Marvin Research was founded in January 1999 by Vincenzo Maresca, M.D., with a team of experts from several CROs. Based in Milan, Italy, the firm focuses on Phase I through Phase IV human clinical trials for multinational pharmaceutical companies. Marvin Research's services span the entire clinical program including preparation of protocols by medical experts, all aspects of monitoring and performance of the trial, and finally statistics and report generation.

    Phidea Marvin Management Team.

    Vincenzo Cocuzza, Chairman and CEO
    Vincenzo Maresca, Managing Director
    Aldo Cocuzza, Managing Director

    For more information regarding Phidea Marvin S.r.l. contact:

    Mr. Aldo Cocuzza, Director,
    +39-3939189389 or email at aldo.cocuzza@phideamarvin.com

    Phidea-Marvin S.r.l.
    International Clinical Research
    Via Cristoforo Colombo, 1.
    Corsico (Milan, Italy)




'/>"/>
SOURCE Phidea Marvin Srl
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research
2. Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment
3. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
4. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
5. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
6. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
7. 2008 Human Research Protection Award Recipients Announced
8. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
9. K-State Researcher Finds Correlation Between Childhood Obesity and Asthma
10. Myeloperoxidase Research Expands
11. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... 18, 2017  Cardinal Health (NYSE: CAH ... 2017 earnings per share (EPS) guidance and providing a ... in conjunction with this morning,s announcement of the planned ... Nutritional Insufficiency businesses. Cardinal Health now believes ... be at the bottom of its previous guidance range ...
Breaking Medicine Technology:
(Date:4/24/2017)... Ga. (PRWEB) , ... April 24, 2017 , ... ... trusted advisor within the telehealth industry, announces the company’s VideoMedicine mobile platform has ... care providers. Available 24 hours a day, Quick Care provides patients with the ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP ... elevated anxiety levels in people with addiction who are served by MAP’s patient ... biosensing wearable device that monitors heart and breath rates to identify anxiety levels ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa ... Walter Blvd, for an educational and exciting 2-day program. , An attendee at ... this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing ...
(Date:4/24/2017)... ... 2017 , ... “Reflections of God’s Work”: an enlightening collection of life lessons ... creation of published author, Jerri Broglin, a survivor of great loss who gained insight ... great eye-opener for those searching for answers, as we are finding the answers that ...
(Date:4/24/2017)... ... 2017 , ... Life of Purpose Treatment is proud to present “An Evening ... at 7:30 pm on May 10th at the University Auditorium. , This benefit concert, ... support the UF Collegiate Recovery Community (UFCRC). The concert will kick off the 5th ...
Breaking Medicine News(10 mins):